Comparative Pharmacology
Head-to-head clinical analysis: DEPEN versus PENTETATE ZINC TRISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPEN versus PENTETATE ZINC TRISODIUM.
DEPEN vs PENTETATE ZINC TRISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
Pentetic acid (diethylenetriaminepentaacetic acid, DTPA) forms stable chelates with metal ions, particularly radioactive transuranic elements such as plutonium, americium, and curium. The zinc trisodium salt exchanges zinc for the radioactive metal, forming a stable, soluble complex that is rapidly excreted via the kidneys, thereby reducing radiation exposure.
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
1 g intravenous infusion over 1-2 hours once daily for up to 5 days.
None Documented
None Documented
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
The terminal elimination half-life is approximately 1.5 to 2 hours for the Zn-DTPA complex in patients with normal renal function. In the setting of acute radiation exposure, this rapid clearance allows for early chelation.
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
Primarily renal elimination of the chelated complex (e.g., Zn-DTPA). In adults, >95% of the administered dose is excreted unchanged in urine within 24 hours, with minor biliary/fecal excretion (<5%).
Category C
Category C
Chelating Agent
Chelating Agent